Skip To Main Content

Artikkelit

Järjestä

Suodattimet

Nollaa
  • Terapia-alue

How to Use Toujeo®

What is Toujeo?

Atopic dermatitis pathophysiology: type 2 inflammation & cytokines

Beneath the skin of patients with AD—type 2 inflammation and the cytokines involved.

Type 1 Diabetes Came as a Surprise in Adulthood – Sara's Story

A little over a year ago, Sara, 34, received life-changing news: She had been diagnosed with type 1 diabetes. A condition often associated with children and adolescents had suddenly appeared in adulthood. The diagnosis meant adjusting to a new daily routine and undergoing significant mental adaptation. It also brought insights and a deeper understanding of herself. Living in Helsinki, Sara openly shares how her life has changed and how even a little humor can help during challenging times.

Future Plans Changed in an Instant – Life with Diabetes

When Kris from Oulu heard two years ago that her 16-year-old son Allan had been diagnosed with type 1 diabetes, her world stopped for a moment. Allan, who lives in Rovaniemi with his father, had been symptomatic for a while, but the family hadn't connected the symptoms to a serious illness. The diagnosis was a shock that permanently changed the family's daily life – and Allan's future dream.

Iisak's Journey: From Transplant Patient to Aspiring Athlete

Patient Support: How to Manage a Serious Illness

BRIGHT publication

The Bright study demonstrated similar efficacy and safety of Toujeo® (Glargine 300 U/ml) compared to degludec 100 U/ml in type 2 diabetes patients who had not previously received basal insulin1.

The RESTORE-G Real World Evidence Study

RESTORE-G: Real-world analysis in insulin-naïve adults with T2D on GLP-1 RA ± OAD(s), intensifying their therapy by starting basal insulin and discontinuing GLP-1 RA, or adding basal insulin to ongoing GLP-1 RA, or initiating a FRC product and discontinuing current GLP-1 RA†2

DELIVER-G: Real-world analysis in insulin-naïve adults with T2DM on GLP-1 RA ± OAD(s), intensifying their therapy by starting basal insulin and discontinuing GLP-1 RA, or adding basal insulin to ongoing GLP-1 RA, or initiating a FRC product and discontinuing current GLP-1 RA†1

DELIVER-G: Real-world analysis in insulin-naïve adults with T2DM on GLP-1 RA ± OAD(s), intensifying their therapy by starting basal insulin and discontinuing GLP-1 RA, or adding basal insulin to ongoing GLP-1 RA, or initiating a FRC product and discontinuing current GLP-1 RA†1

Advancing Treatment for Uncontrolled AD and PN: New Approaches

As we continue to advance in our understanding and treatment capabilities, our response to uncontrolled AD and PN becomes more effective, paving the way for a future where patients can lead healthier, more comfortable lives8.

Underneath the Skin: Hidden Challenges of Uncontrolled AD and PN

What are the hidden challenges of living with uncontrolled Atopic Dermatitis (AD) and Prurigo Nodularis (PN)?